|
PUBLICATIONS
Luis Menéndez, Agustín Hidalgo, Álvaro Meana, Hervé Poras, Marie-Claude Fournié-Zaluski,Bernard P. Roques, Ana Baamonde. Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin Article in Press in European Journal of Pharmacology Anne C, Turcaud S, Quancard J, Teffo F, Meudal H, Fournie-Zaluski MC, Roques BP. Development of potent inhibitors of botulinum neurotoxin type B. J Med Chem. 2003 Oct 23;46(22):4648-56
Anne C, Blommaert A, Turcaud S, Martin AS, Meudal H, Roques BP. Thio-derived disulfides as potent inhibitors of botulinum neurotoxin type B: implications for zinc interaction. Bioorg Med Chem. 2003 Oct 15;11(21):4655-60.
Mock M, Roques BP. Progress in rapid screening of Bacillus anthracis lethal factor activity.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6527-9.
Anne C, Cornille F, Lenoir C, Roques BP. High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal Biochem. 2001 Apr 15;291(2):253-61.
Roques BP, Anne C, Turcaud S, Fournie-Zaluski MC. Mechanism of action of clostridial neurotoxins and rational inhibitor design. Biol Cell. 2000 Sep;92(6):445-7. Review.
Cornille F, Roques BP. [Tetanus and botulinum toxins are zinc metallopeptidases: molecular mechanisms and inhibition of their neurotoxicity] J Soc Biol. 1999;193(6):509-16. Review. French.
Martin L, Cornille F, Turcaud S, Meudal H, Roques BP, Fournie-Zaluski MC. Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach. J Med Chem. 1999 Feb 11;42(3):515-25.
Cornille F, Martin L, Lenoir C, Cussac D, Roques BP, Fournie-Zaluski MC. Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J Biol Chem. 1997 Feb 7;272(6):3459-64.
Cornille F, Deloye F, Fournie-Zaluski MC, Roques BP, Poulain B. Inhibition of neurotransmitter release by synthetic proline-rich peptides shows that the N-terminal domain of vesicle-associated membrane protein/synaptobrevin is critical for neuro-exocytosis. J Biol Chem. 1995 Jul 14;270(28):16826-32.
Inguimbert N, Coric P, Dhotel H, Bonnard E, Llorens-Cortes C, Mota N, Fournie-Zaluski MC, Roques BP. Synthesis and in vitro activities of new non-peptidic APA Inhibitors. J Pept Res. 2005 Feb;65(2):175-88.
Lawnicka H, Potocka AM, Juzala A, Fournie-Zaluski MC, Pawlikowski M. Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro.
Med Sci Monit. 2004 Nov;10(11):BR410-3. Epub 2004 Oct 26
Stragier B, Sarre S, Vanderheyden P, Vauquelin G, Fournie-Zaluski MC, Ebinger G, Michotte Y. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem. 2004 Sep;90(5):1251-7.
Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P, Roques BP, Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7775-80. Epub 2004 May 10
Inguimbert N, Poras H, Dhotel H, Beslot F, Scalbert E, Bennejean C, Renard P, Fournie-Zaluski MC, Roques BP. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
J Pept Res. 2004 Feb;63(2):99-107.
Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr D Biol Crystallogr. 2004 Feb;60(Pt 2):392-6. Epub 2004 Jan 23.
Le Guen S, Mas Nieto M, Canestrelli C, Chen H, Fournie-Zaluski MC, Cupo A, Maldonado R, Roques BP, Noble F. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone.
Pain. 2003 Jul;104(1-2):139-48.
|
